Wells Fargo’s Caris Life Sciences CAI Stock Holding History

Wells Fargo’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-113,500	Closed	-$3.06M	–	7527
2025 Q4	$3.06M	Buy	+113,500	New	+$3.2M	﹤0.01%	3102

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHWEPV

J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

SSP

Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return

PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wells Fargo's CAI Position: Q2 2026 in Review

Wells Fargo increased its Caris Life Sciences (CAI) stake by 37% in Q2 2026, buying an estimated $115K and bringing the position to 23,689 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #4745.

Wells Fargo first reported a position in CAI in Q2 2025 and has held it in 5 quarters since. 247 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

Wells Fargo held 23,689 shares of Caris Life Sciences worth $422K as of Q2 2026.
Wells Fargo bought 6,439 Caris Life Sciences shares in Q2 2026, an estimated $115K.
Caris Life Sciences made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4745 holding.
Wells Fargo first reported a position in Caris Life Sciences in Q2 2025 and has held it in 5 quarters since.
247 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.